CN112778220A - 一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 - Google Patents
一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 Download PDFInfo
- Publication number
- CN112778220A CN112778220A CN201911063162.9A CN201911063162A CN112778220A CN 112778220 A CN112778220 A CN 112778220A CN 201911063162 A CN201911063162 A CN 201911063162A CN 112778220 A CN112778220 A CN 112778220A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- preparation
- benzodiazepine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- -1 benzodiazepine compound Chemical class 0.000 title claims abstract description 15
- 229940049706 benzodiazepine Drugs 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010077895 Sarcosine Proteins 0.000 claims abstract description 12
- 229940043230 sarcosine Drugs 0.000 claims abstract description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 8
- 238000007112 amidation reaction Methods 0.000 claims abstract description 6
- 238000005917 acylation reaction Methods 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract 5
- 238000006243 chemical reaction Methods 0.000 description 41
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- SZCPTRGBOVXVCA-UHFFFAOYSA-N 2-amino-6-chlorobenzoic acid Chemical compound NC1=CC=CC(Cl)=C1C(O)=O SZCPTRGBOVXVCA-UHFFFAOYSA-N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- BGWXTSKOBMAJMO-UHFFFAOYSA-N 2,6-dichloro-3,5-bis(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=C(Cl)N=C1Cl BGWXTSKOBMAJMO-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- JCYLWUVDHLVGER-UHFFFAOYSA-N evt-201 Chemical compound O1C(CN(C)C)=NC(C2=C3N(C4=CC=CC(Cl)=C4C(=O)N(C)C3)C=N2)=N1 JCYLWUVDHLVGER-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 238000011112 process operation Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了一种苯并二氮杂
Description
技术领域
背景技术
EVT201是一种GABAA受体部分激动变构调节剂,其选择性作用于苯二氮受体α1亚型,对该受体复合物表现出高的亲和性和中等强度的激动作用。与传统的苯二氮类GABA受体完全激动剂类相比,EVT201在运动障碍、后遗效应、耐受性、乙醇相互作用、身体依赖性、记忆力损伤等不良反应方面具有明显的优势。苯并二氮杂二酮化合物D是制备EVT201的关键中间体,结构如下式:
目前对该化合物D的制备方法已有相关文献报道。文献CN1350538A或CN101426771A公开的合成路线如下:
6-氯-靛红酸酐与肌氨酸混悬在对二甲苯中加热回流2小时。冷却至室温进一步搅拌1小时,过滤、洗涤、真空干燥。在0℃下,所得的固体在去离子水中消化1小时,过滤、洗涤、真空干燥得到,收率约88%。反应温度高,工艺操作繁琐,原料价格昂贵较难获得,溶剂毒性大、不环保。
文献US4352817公开的合成路线如下:
6-氯-靛红酸酐与肌氨酸在二甲亚砜下加热至110℃反应1小时,减压浓缩溶剂,乙醇重结晶得到。原料价格昂贵,较难获得,产品需要重结晶纯化,溶剂沸点高,难回收。
综上所述,目前关于化合物D的合成文献报道中均需以6-氯靛红酸酐为起始原料制备,原料价格昂贵,较难获得;后处理需要低温消化或重结晶纯化,工艺操作繁琐;溶剂沸点高不利于回收,毒性大、不环保等,这些不利因素限制了该化合物D的工业化生产。
发明内容
本发明的制备方法具体包括下述步骤:
(1)在有机溶剂存在下,化合物SM01与N,N-二羰基咪唑进行酰化反应得到中间体B;
(2)中间体B与肌氨酸进行酰胺化反应得到中间体C;
(3)中间体C在酸存在下进行关环反应得到化合物D。
所述的化合物D的制备方法中,步骤(1)的酰化反应方法、步骤(2)的酰胺化反应方法、步骤(3)的关环反应方法可以为本领域中该类反应的常规方法,本发明中特别优选以下反应条件:
其中,步骤(1)中所述的有机溶剂为本领域内该类反应常规的有机溶剂,例如乙腈、二氯甲烷、1,2-二氯乙烷、1,4-二氧六环、四氢呋喃和甲基四氢呋喃中的一种或几种,优选1,4-二氧六环、乙腈。
步骤(1)所述的有机溶剂的用量为本领域内该类反应常规的用量,例如所述的有机溶剂与所述的化合物SM01的体积质量比值为5mL/g~15mL/g,优选10mL/g。
步骤(1)中所述的N,N-二羰基咪唑与所述的化合物SM01的摩尔比值为1.2~2.0∶1,优选1.5∶1。
步骤(2)中所述的肌氨酸与所述的化合物SM01的摩尔比值为1.2~2.0∶1,优选1.2∶1。
步骤(2)中所述的酰胺化反应的时间为10h~24h,优选15h~20h。
步骤(3)中所述的酸为本领域内该类反应常规的酸,例如多聚磷酸、磷酸、甲磺酸和硫酸中的一种或几种,优选硫酸、多聚磷酸。
步骤(3)所述的酸的用量可以为本领域内该类反应常规的用量,例如所述的酸与所述的化合物SM01的摩尔比值为1.2~4.0∶1,优选3.0∶1。
步骤(3)中所述的关环反应的温度为45℃~100℃,优选65℃~90℃。
步骤(3)中所述的关环反应的时间为5h~24h,优选9h~16h。
根据本发明,一个优选的实施方案如下:
于反应瓶中加入原料6-氯2-氨基苯甲酸(60g,0.35mol),1,4-二氧六环(600mL),搅拌,室温加入N,N-二羰基咪唑(85.1g,0.52mol,1.5eq),加完,室温反应16小时后,得中间体B。
然后直接往所得中间体B的反应液中加入肌胺酸(37.4g,0.42mol,1.2eq),室温反应16小时后,得中间体C。
然后冰水浴降温至5℃后,在往所得中间体C的反应液中,滴加浓硫酸(102.9g,1.1mol,3eq),加完,升温90℃反应16h,降温,减压浓缩,加水(600mL),搅拌1h,过滤,水洗涤,50℃烘干得产品D。
本发明还提供了一种如式B所述的化合物:
本发明还提供了一种如式C所述的化合物:
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:
(2)工艺操作简单,不需要低温消化或重结晶纯化,所得产品收率及纯度高。
(3)避免了使用高沸点溶剂,溶剂易于回收,降低生产成本,适宜工业化生产。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
实施例1
于反应瓶中加入原料6-氯2-氨基苯甲酸(80g,0.47mol),1,4-二氧六环(800mL),搅拌,室温加入N,N-二羰基咪唑(113.4g,0.70mol,1.5eq),加完,室温反应16小时后,得中间体B。LC-MS:M++1=222.1。
然后直接往所得中间体B的反应液中加入肌胺酸(50.94g,0.56mol,1.2eq),室温反应16小时后,得中间体C。LC-MS:M++1=243.1。
然后冰水浴降温至5℃后,在往所得中间体C的反应液中,滴加浓硫酸(138.3g,1.41mol,3eq),加完,升温90℃反应12h,降温,减压浓缩,加水(800mL),搅拌1h,过滤,水洗涤,50℃烘干得产品D(99.8g,摩尔收率为94.56%)。LC-MS:M++1=225.1,HPLC纯度为98.05%。
实施例2
于反应瓶中加入原料6-氯2-氨基苯甲酸(60g,0.35mol),1,4-二氧六环(600mL),搅拌,室温加入N,N-二羰基咪唑(85.1g,0.52mol,1.5eq),加完,室温反应16小时后,得中间体B。LC-MS:M++1=222.1。
然后直接往所得中间体B的反应液中加入肌胺酸(37.4g,0.42mol,1.2eq),室温反应16小时后,得中间体C。LC-MS:M++1=243.1。
然后冰水浴降温至5℃后,在往所得中间体C的反应液中,滴加浓硫酸(102.9g,1.1mol,3eq),加完,升温90℃反应16h,降温,减压浓缩,加水(600mL),搅拌1h,过滤,水洗涤,50℃烘干得产品D(74.1g,摩尔收率为94.27%)。LC-MS:M++1=225.1,HPLC纯度为98.15%。
实施例3
于反应瓶中加入原料6-氯2-氨基苯甲酸(50g,0.29mol),乙腈(600mL),搅拌,室温加入N,N-二羰基咪唑(70.9g,0.44mol,1.5eq),加完,室温反应16小时后,得中间体B。LC-MS:M++1=222.1。
然后直接往所得中间体B的反应液中加入肌胺酸(31.2g,0.35mol,1.2eq),室温反应12小时后,得中间体C。LC-MS:M++1=243.1。
然后冰水浴降温至5℃后,在往所得中间体C的反应液中,滴加浓硫酸(85.3g,0.87mol,3eq),加完,升温85℃反应16h,降温,减压浓缩,加水(500mL),搅拌1h,过滤,水洗涤,50℃烘干得产品D(61.3g,摩尔收率为94.10%)。LC-MS:M++1=225.1,HPLC纯度为97.85%。
实施例4
于反应瓶中加入原料6-氯2-氨基苯甲酸(45g,0.26mol),1,4-二氧六环(450mL),搅拌,室温加入N,N-二羰基咪唑(63.79g,0.39mol,1.5eq),加完,室温反应16小时后,得中间体B。LC-MS:M++1=222.1。
然后直接往所得中间体B的反应液中加入肌胺酸(28.0g,0.31mol,1.2eq),室温反应15小时后,得中间体C。LC-MS:M++1=243.1。
然后冰水浴降温至5℃后,在往所得中间体C的反应液中,滴加多聚磷酸(263.5g,0.78mol,3eq),加完,升温85℃反应14h,降温,减压浓缩,加水(450mL),搅拌1h,过滤,水洗涤,50℃烘干得产品D(54.8g,摩尔收率为93.88%)。LC-MS:M++1=225.1,HPLC纯度为98.20%。
核磁数据如下:
中间体B:1H NMR(400MHz,DMSO-d6)δ8.73(s,1H),8.03(d,1H),7.30(d,1H),7.25(d,1H),6.95-7.15(m,1H),6.62(d,1H),6.27(br,2H);
13C NMR(101MHz,DMSO)δ167.65,152.50,136.8,136.60,135.11,130.75,123.65,120.55,117.60,114.85。
中间体C:1H NMR(400MHz,DMSO-d6)613.03(bs,1H),6.95-7.15(m,1H),6.64(d,1H),6.58(d,1H),5.18(br,s,2H),4.65(s,2H),3.25(s,3H);
13C NMR(101MHz,DMSO)δ173.25,169.50,149.60,132.65,131.85,121.50,119.75,114.25,55.85,35.95。
化合物D:1H NMR(400MHz,DMSO-d6)68.83(s,1H),6.96-7.68(m,3H),4.14(s,2H),3.25(s,3H);
13C NMR(101MHz,DMSO)6168.25,161.50,141.60,132.11,131.25,126.80,125.40,117.20,56.70,35.48。
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911063162.9A CN112778220B (zh) | 2019-11-02 | 2019-11-02 | 一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911063162.9A CN112778220B (zh) | 2019-11-02 | 2019-11-02 | 一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112778220A true CN112778220A (zh) | 2021-05-11 |
CN112778220B CN112778220B (zh) | 2024-06-07 |
Family
ID=75748730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911063162.9A Active CN112778220B (zh) | 2019-11-02 | 2019-11-02 | 一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112778220B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355637B1 (en) * | 1999-10-01 | 2002-03-12 | Advanced Medicine, Inc. | Local anesthetic compounds |
CN1350538A (zh) * | 1999-05-12 | 2002-05-22 | 弗·哈夫曼-拉罗切有限公司 | 咪唑二氮杂䓬衍生物 |
-
2019
- 2019-11-02 CN CN201911063162.9A patent/CN112778220B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1350538A (zh) * | 1999-05-12 | 2002-05-22 | 弗·哈夫曼-拉罗切有限公司 | 咪唑二氮杂䓬衍生物 |
US6355637B1 (en) * | 1999-10-01 | 2002-03-12 | Advanced Medicine, Inc. | Local anesthetic compounds |
Non-Patent Citations (2)
Title |
---|
BAKAVOLI, M.,等: "Convenient synthesis of some optically active 1, 4-benzodiazepin-2, 5-diones", 《CHINESE CHEMICAL LETTERS》, vol. 19, no. 1, pages 12 - 14, XP022399553, DOI: 10.1016/j.cclet.2007.10.043 * |
刘鹰翔: "《药物合成反应》", 全国中医药出版社, pages: 134 * |
Also Published As
Publication number | Publication date |
---|---|
CN112778220B (zh) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013026391A1 (zh) | 嘧菌酯及其合成中专用中间体的合成方法 | |
KR20170131508A (ko) | 레디파스비르 및 이의 유도체의 제조방법 및 레디파스비르를 제조하기 위한 중간체 화합물 | |
JP2021504418A (ja) | 2−(5−メトキシイソクロマン−1−イル)−4,5−ジヒドロ−1h−イミダゾールおよびその硫酸水素塩の製造方法 | |
CN114685468A (zh) | 用于治疗子宫肌瘤的药物的中间体化合物及其制备方法 | |
CN114315823B (zh) | 盐酸小檗碱及其类似物的中间体及其制备方法 | |
JP2005507900A (ja) | シタロプラムの製造方法 | |
JP2004500324A (ja) | ピペラジン環含有化合物の新規の合成及び結晶化 | |
CN113416150A (zh) | 一种洛铂中间体的新合成方法 | |
CN112778220A (zh) | 一种苯并二氮杂䓬二酮化合物d的制备方法及其中间体 | |
CN114591140B (zh) | 孟鲁司特钠中间体及其制备方法和应用该中间体的制备方法 | |
US6545149B2 (en) | Synthesis and crystallization of piperazine ring-containing compounds | |
CN114057678A (zh) | 一种1-溴-3-氯二苯并呋喃的合成方法 | |
CN110563721A (zh) | 一种新的盐酸阿扎司琼的制备方法 | |
WO2020125581A1 (zh) | 一种类酰胺类衍生物及其中间体的制备方法 | |
US20160168161A1 (en) | Method for producing heterocyclic compound | |
CN112358447B (zh) | 7-氟异喹啉-1-羧酸的合成方法 | |
CN112552154B (zh) | 一种1-溴芴酮的制备方法 | |
CN115572262B (zh) | 一种异喹啉衍生物及其制备方法 | |
CN116813525B (zh) | 一种多乙酰基取代的氧化吲哚类化合物的合成方法 | |
JP6917612B2 (ja) | ペリレンテトラカルボン酸二無水物の臭素一置換体の製造方法及び精製方法。 | |
CN117551038A (zh) | 一种硼酸促进4-溴-7-甲基-1h-吲唑关环制备的合成方法 | |
JP2767295B2 (ja) | インドール―3―カルボニトリル化合物の製造方法 | |
US20040176591A1 (en) | Novel synthesis and crystallization of peperazine ring-containing compounds | |
CN116947592A (zh) | 一种2,7-二氯芴衍生物的制备方法 | |
CN117486904A (zh) | 一种更昔洛韦杂质的合成与精制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |